Rapport Therapeutics, Inc. Common Stock (RAPP) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
| Previous Close | 48.24 |
| Open | 48.16 |
| Day High | 50.25 |
| Day Low | 47.44 |
| 52-Week High | 50.34 |
| 52-Week Low | 14.11 |
| Volume | 365,421 |
| Average Volume | 353,196 |
| Market Cap | 2.36B |
| PE | -16.23 |
| EPS | -3.04 |
| Moving Average 50 Days | 42.34 |
| Moving Average 200 Days | 33.73 |
| Change | 1.09 |
Rapport Therapeutics and Tenacia Biotechnology Announce Strategic Collaboration for the Development and Commercialization of RAP-219 in Greater China
GlobeNewswire Inc.
Mar 09, 2026 11:00 AM GMT
Partnership leverages Tenacia’s expertise in central nervous system (CNS) drug development and commercialization to accelerate U.S. and global development of RAP-219 Tenacia obtains exclusive rights to develop and commercialize RAP-219 in Greater Chi
Rapport Therapeutics Announces Accelerated Initiation of RAP-219 Phase 3 Program, Expansion of Epilepsy Portfolio, and Continued Progress Across the Pipeline
GlobeNewswire Inc.
Jan 07, 2026 12:00 PM GMT
U.S. Food and Drug Administration (FDA) allows advancement of RAP-219 into registrational trials for focal onset seizures (FOS); accelerated initiation of Phase 3 program expected in the second quarter of 2026 On strength of RAP-219 Phase 2a FOS dat
Rapport Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
GlobeNewswire Inc.
Dec 18, 2025 12:00 PM GMT
BOSTON and SAN DIEGO, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines